Pristine nanotubes produced through a new process can be modified to carry drugs to tumors through gaps in blood-vessel walls that larger particles cannot fit through. The nanotubes may then target and infiltrate the cancerous cells' nuclei, where the drugs can be released through sonication.
Pristine nanotubes produced through a new process developed at Rice can be modified to carry drugs to tumors through gaps in blood-vessel walls that larger particles cannot fit through.
The nanotubes may then target and infiltrate the cancerous cells' nuclei, where the drugs can be released through sonication -- that is, by shaking them.
The research led by Rice chemist Andrew Barron was reported in the Royal Society of Chemistry's Journal of Materials Chemistry B.
Most pancreatic cancer patients die within a year of diagnosis and have a five-year survival rate of 6 percent, partially because there is no method for early detection, according to the American Cancer Society. Tumors are often inoperable and pancreatic cancer cells are also difficult to reach with chemotherapy, said co-author Jason Fleming, a professor of surgical oncology at MD Anderson.
"These findings are encouraging because they offer a potential delivery solution for pancreatic cancer patients whose tumors resist standard chemotherapy," Fleming said. "There are molecular and biological barriers to efficient delivery of chemotherapy to pancreatic cancer tumors, and these nanotubes might be able to make some of those irrelevant."
Report: http://bit.ly/1rRap1q
Source: ScienceDaily
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More